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Summary A prospective, noninterventional survey was 
conducted among Clostridium diicile positive patients 
identiied in the time period of July until October 2012 
in 18 hospitals distributed across all nine Austrian prov-
inces. Participating hospitals were asked to send stool 
samples or isolates from ten successive patients with C. 
diicile infection to the National Clostridium diicile Ref-
erence Laboratory at the Austrian Agency for Health and 
Food Safety for PCR-ribotyping and in vitro susceptibil-
ity testing. A total of 171 eligible patients were identiied, 
including 73 patients with toxin-positive stool specimens 
and 98 patients from which C. diicile isolates were pro-
vided. Of the 159 patients with known age, 127 (74.3 %) 
were 65 years or older, the median age was 76 years (range: 
9–97 years), and the male to female ratio 2.2. Among these 
patients, 73 % had health care-associated and 20 % com-
munity-acquired C. diicile infection (indeterminable 
7 %). he all-cause, 30-day mortality was 8.8 % (15/171). 
Stool samples yielded 46 diferent PCR-ribotypes, of 
which ribotypes 027 (20 %), 014 (15.8 %), 053 (10.5 %), 
078 (5.3 %), and 002 (4.7 %) were the ive most prevalent. 
Ribotype 027 was found only in the provinces Vienna, 
Burgenland, and Lower Austria. Severe outcome of C. dif-
icile infection was found to be associated with ribotype 
053 (prevalence ratio: 3.04; 95 % CI: 1.24, 7.44), not with 
the so-called hypervirulent ribotypes 027 and 078. All 
027 and 053 isolates exhibited in vitro resistance against 
moxiloxacin. Fluoroquinolone use in the health care set-
ting must be considered as a factor favoring the spread of 
these luoroquinolone resistant C. diicile clones.
Keywords Ribotype  · Moxiloxacin  · Resistance  · Noso-
comial · Mortality
Introduction
Clostridium diicile is a major identiiable infectious cause 
of nosocomial diarrhea [1, 2]. Clinical manifestations of C. 
diicile infection (CDI) range from asymptomatic carriage 
to diarrhea, pseudomembranous colitis, toxic megacolon, 
and death. In recent years, an increase of CDI has been 
reported, in part due to the spread of one speciic clone, 
polymerase chain reaction (PCR) ribotype 027 [3–6]. PCR 
ribotype 078, which has been associated with both food of 
animals and humans, is an additional emerging strain of 
C. diicile in Europe and the USA [7, 11]. Little is known 
about the current dominant ribotypes of C. diicile among 
the hospitalized patients in Austria [1].
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he primary objective of our study was to ascertain the 
frequency distribution of C. diicile ribotypes among C. 
diicile positive patients hospitalized in Austrian hospi-
tals in 2012. he secondary objective was to investigate 
the association between the most prevalent ribotypes 
found and the setting of C. diicile acquisition (health 
care setting or community), the resistotypes, and the 
severity of CDI.
Patients, materials and methods
Study design and data collection
A prospective, non-interventional, descriptive, and 
analytical survey was conducted on C. diicile positive 
patients identiied within a 4-month period, from July 
until October 2012 in 18 hospitals distributed across all 
nine Austrian provinces. he laboratories of these partic-
ipating hospitals (one hospital per province, aside from 
Vienna, where ten hospitals participated) were asked to 
send either C. diicile toxin(s) positive specimens or C. 
diicile isolates obtained from ten successive C. diicile 
positive patients to the National Clostridium diicile Ref-
erence Laboratory at the Austrian Agency for Health and 
Food Safety (AGES). By using a standardized question-
naire, infection control oicers collected information by 
reviewing study patients’ medical charts on demograph-
ics (sex, age), clinical signs (diarrhea deined by using 
Bristol stool chart typing, toxic megacolon, pseudomem-
branous colitis deined by gastro-intestinal endoscopy or 
computed tomography), epidemiological case classiica-
tion (health care-associated (HA), indeterminable, and 
community-acquired (CA)), and on CDI-severity deined 
by need of surgical intervention, intensive care, or all-
cause 30-day mortality. In case of hospital stay less than 
30 days, information on all-cause 30-day mortality was 
ascertained by postdischarge interviews with the study 
patient or their relatives. In case of no postdischarge 
contact, hospital admission registers were consulted 
regarding readmission of the study patient within 30 days 
following previous admission to the study hospital [12]. 
According to the case deinition for the mandatory C. 
diicile enhanced surveillance scheme in UK, any of the 
following deined a C. diicile infection case in patients: 
diarrheal stools or toxic megacolon, from which a speci-
men tested positive for toxigenic C. diicile [4].
Our survey was classiied as an “active surveillance 
study” and therefore did not require ethical approval. 
None of the test results was used to alter individual 
patient care. All patient demographic data collected were 
anonymous.
Laboratory investigation
In case of toxin positive stool specimens, toxigenic cul-
ture was performed by spreading specimens on C. dif-
icile agar (CLO agar containing cycloserine 0.1  g/l, 
cefoxitin 0.008  g/l, and amphotericin B 0.002  g/l; bio-
Mérieux, Marcy l’Etoile, France) and incubation at 
35 ± 2 °C in an anaerobic atmosphere (< 1 % oxygen, ≥ 13 % 
carbon dioxide), in anaerobic jars for 48 h [13]. Simulta-
neously the stool specimens were enriched in thioglycol-
late broth with vitamin K (0.5 mg/l) and hemin (5 mg/l) 
(Heipha Dr. Müller GmbH, Eppelheim, Germany) and 
incubated anaerobically at 35 ± 2 °C for 2–7 days. One 
20  µl-portion, taken from the broth near the bottom of 
the tube, was plated directly onto C. diicile selective 
agar (CLO; bioMérieux) and incubated for 48 h anaero-
bically as described above. Putative C. diicile colonies 
were conirmed by testing for the common antigen (C. 
diicile agglutination test kit; Microgen, Camberley, UK) 
and by mass spectrometry (matrix assisted laser desorp-
tion/ionization-time of light (MALDI-TOF) Biotyper; 
Bruker Daltonics, Bremen, Germany). Toxin produc-
tion of strains isolated on CLO- or Columbia blood-agar 
(both from bioMérieux) was tested using a Toxin A + B 
ELFA (enzyme linked luorescent assay) test (Vidas, bio-
Mérieux). Ribotyping was performed as described else-
where [14]. In vitro susceptibility testing was performed 
as described previously [15]. Briely, agar-difusion test-
ing was performed on Brucella agar plates supplemented 
with hemin (5  µg/ml), vitamin K1 (1  µg/ml), and lysed 
sheep blood (5 % v/v) using epsilometer test (Etest®) 
(AB-Biodisk, Solna, Schweden) and the respective Euro-
pean Committee on Antimicrobial Susceptibility Test-
ing (EUCAST) minimal inhibitory concentration (MIC) 
breakpoints for metronidazole and vancomycin, Clinical 
and Laboratory Standards Institute (CLSI) MIC break-
points for clindamycin and moxiloxacin, and the sug-
gested MIC breakpoints for rifampicin and an in-house 
disc (40 µg) difusion test for rifaximin, as described by 
Huhulescu et al. [15].
Bacteroides fragilis ATCC 25285 and C. diicile ATCC 
700057 were used as quality control strains. In order to 
investigate associations between ribotype and C. dii-
cile in vitro susceptibility to metronidazole, vancomycin, 
clindamycin, moxiloxacin, and rifampicin, resistotypes 
were deined as presented in Table  1. For analyses, 
reduced antimicrobial susceptibility (i.e., intermediate) 
was considered as resistant.
Statistical analyses
Single proportion estimates were provided with 95 % 
conidence interval. Prevalence ratios (PRs) and 95 % 
conidence intervals (CIs) are presented for associations 
between the ive most prevalent ribotypes (considered as 
single explanatory variables) and the outcome variables 
comprising the setting of C. diicile acquisition (health 
care setting or community, as deined below) resistotype 
(0, 1, 2, 3, 4, 5, 6, 7, deined as presented in Table 1), and 
the severity of disease deined as all-cause death within 
30 days following C. diicile detection or requiring inten-
sive care or surgical intervention.
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12 patients, the location of CD acquisition was indeter-
minable. For all 171 patients, isolates were available for 
ribotyping. A total of 46 diferent ribotypes were identi-
ied, of which PCR-ribotype (RT) 027 (20 %), 014 (15.8 %), 
053 (10.5 %), 078 (5.3 %), and RT 002 (4.7 %) were the ive 
most prevalent, accounting for 96 of the 171 (56 %) iso-
lates. he PCR-ribotypes 027 and 053 were found only 
in patients from hospitals situated in East-Austria, com-
prised of Vienna, Burgenland, and Lower Austria; RT 014 
was found in patients across all nine Austrian provinces 
and RT 078 was identiied in patients from hospitals sit-
uated in Vienna and in ive other provinces situated in 
South-, North-, and West-Austria (Table 2).
Study patients 65 years and older were 3.81 times 
more frequently positive for RT053 as compared to study 
patients less than 65, at borderline statistical signiicance 
(95 %CI: 0.91, 15.96; p= 0.06). No other dominate ribotype 
was found to be signiicantly associated with age.
Table  3 displays results of the in vitro antimicrobial 
susceptibility testing of the C. diicile isolates, segre-
gated into the ive most frequent ribotypes found among 
the study participants. All isolates were susceptible to 
metronidazole and vancomycin. C. diicile RT 002 iso-
lates were 2.4 (95 % CI: 1.31, 4.29; p = 0.04) and RT 014 
1.8 (PR: 1.78; 95 % CI: 1.07, 2.95, p = 0.0391) times more 
frequently found to be susceptible to all ive antibiotics 
tested (“resistotype 0”), as compared each to all other 
identiied ribotypes. All RT 027 (n= 27) and RT 053 iso-
lates (n= 18) showed resistance against moxiloxacin. RT 
027 displayed almost ive times more frequently (95 %CI: 
2.22, 10.93; p< 0.001) monoresistance to moxiloxacin 
(resistotype 2), almost three times more frequently (95 % 
CI: 1.74, 4.94; p< 0.001) clindamycin/moxiloxacin resis-
tance (resistotype 4), and 12 times more frequently (95 % 
CI: 1.30, 112.62; p= 0.0252) moxiloxacin/rifampicin 
resistance (resistotype 6), as compared to all other ribo-
types. PCR-RT 053 exhibited clindamycin/moxiloxacin 
resistance almost four times more frequently (95 %CI: 
2.43, 6.33; p= 0.000), as compared to the other ribotypes, 
and the tri-resistance against clindamycin/moxiloxa-
cin/rifampicin (resistotype 7) 5.3 times more frequently 
than all other ribotypes (95 % CI: 1.94, 14.51). RT 078 was 
not found to be associated with any of the seven resisto-
types tested. Ribotype 053 was the single ribotype found 
to be associated with severe CDI (PR: 3.04; 95 %CI: 1.24, 
7.44; p= 0.012) (Table 4), also after adjustment for age.
All of the ive most prevalent ribotypes were found to 
be more frequently acquired in the health care setting 
than in the community.
Discussion
he global emergence of CDI in the past decade fol-
lowed highly-publicized C. diicile outbreaks in the USA 
and Canada that were associated with increased rates of 
disease recurrence and mortality [17–19]. he outbreaks 
were caused by a previously uncommon, luoroquino-
lone resistant variant of C. diicile genotyped as ribotype 
A C. diicile infection case in a patient, who had symp-
tom onset prior to or within 72 h after hospital admission, 
was classiied as health care facility-associated (HCFA), if 
the patient had been discharged from a healthcare facil-
ity within the previous 4 weeks and classiied as inde-
terminable, if the patient had been discharged from a 
healthcare facility within the previous 4–12 weeks. A case 
of C. diicile infection in a patient, who had not been dis-
charged from a healthcare facility (including hospital, 
nursing home, or other health care facilities) in the pre-
vious 12 weeks, was classiied as community-acquired 
(CA-CDI) [16].
Associations were tested for signiicance by Pearson’s 
qui-squared test or Fisher’s exact test at a signiicance 
level of 5 %. Data entry and analyses were performed 
using Epi Data software (Epi-Info 3.3.2 [Centers for Dis-
ease Control and Prevention] for Windows [Microsoft 
Corp, Redmond, WA]) and STATA 10.5 (STATA Corp, Col-
lege Station, TX).
Results
From July until October 2012, 171 hospitalized patients 
with stool specimen positive for toxigenic C. diicile were 
included in our survey. he study patients consisted of 73 
patients from which C. diicile toxin positive stool speci-
mens, and of 98 patients from which C. diicile isolates 
were provided.
Of the 159 patients with known age, 127 (74.2 %) were 
65 years or older, the median age was 76 years (range: 
9–97 years), and the male to female ratio 2.2. Out of 
the 171 study patients, 162 (94.7 %) had diarrhea (Bris-
tol Stool Chart types 5–7), 3 patients had exclusively 
abdominal cramps or vomiting, and 5 patients presented 
without any clinical signs compatible with a case of C. 
diicile infection. A total of 4.7 % (8/171), 1.2 % (2/171), 
and 8.8 (15/171) respectively, developed a severe disease 
in terms of requiring intensive care, surgical interven-
tion, and fatal outcome, respectively. In 73.1 % (n= 125) 
of the 171 study patients, CDI was likely acquired in the 
health care setting and in 19.9 % in the community; for 
Table 1 Definition of the resistotypes based on the results 
of in vitro susceptibility testing for metronidazole (metro), 
vancomycin (vanco), clindamycin (clinda), moxifloxacin 
(moxi), and rifampicin (rifam)
Resistotypes Antibiotics
Metro Vanco Clinda Moxi Rifam
Resistotype 0 S S S S S
Resistotype 1 S S R S S
Resistotype 2 S S S R S
Resistotype 3 S S S S R
Resistotype 4 S S R R S
Resistotype 5 S S R S R
Resistotype 6 S S S R R
Resistotype 7 S S R R R
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tifying any further C. diicile RT 027 isolates until 2008. 
In 2008, a steep increase in the number of cases of RT 027 
infections was observed, all originating from four Vien-
nese hospitals. From November 2008 to mid-April 2009, 
36 patients with C. diicile RT 027 infection were identi-
ied at the National Reference Laboratory [23]. Although 
the outbreak apparently ceased, our current indings 
4 years later demonstrate the remaining dominance of 
RT 027 in Vienna (34 of 92 CDI-cases from the 10 Vien-
nese hospitals). In addition to Vienna, the surrounding 
province Lower Austria (3 of 9 CDI-cases) and the neigh-
boring province Burgenland (4 of 8 CDI-cases) were also 
afected by RT 027, in contrast to the remaining six other 
federal provinces. he observed dominance of RT 027 
in patients from hospitals in Eastern Austria could be 
disputed as due to a selection bias in view of the over-
representativeness of the hospitals in the eastern prov-
027. A European hospital-based study [1] together with a 
US analysis of C. diicile ribotype data by Walk et al. [20] 
indicated that the most frequent ribotypes in the indus-
trialized world are 014, 020, 027, and 078.
We found 027 to be the most prevalent ribotype, 
accounting for 20 % of all isolates from the 171 hospi-
talized, C. diicile positive patients. he second most 
prevalent ribotype was 014, followed by RT 053, RT 078, 
and RT 002. In Austria, the irst case of C. diicile RT 027 
was identiied in a 69-year-old British woman admitted 
to a local hospital in the Austrian western province Tyrol 
in 2006 [21]. In April 2008, C. diicile RT 027 infections 
were irst identiied in Austrian citizens, one hospitalized 
in Styria, a southern province, and one in Vienna [22]. 
Since August 2006, the C. diicile Reference Laboratory 
ribotyped approximately 2700 human C. diicile isolates, 
received from all nine Austrian provinces, without iden-
Table 2 The five most frequent PCR ribotypes of toxigenic C. difficile from 171 hospital patients by province of participating 
hospitals
Austria ProvincesNumber of C. difficile isolates
East-Austria South-Austria North-Austria West-Austria
Vienna Burgenland Lower Austria Carinthia Styria Upper Austria Salzburg Tyrol Vorarlberg
Ribotypes N = 171 
n (%)
n
1
 = 92 
n (%)
n
2
 = 8 
n (%)
n
3
 = 9 
n (%)
n
4
 = 11 
n (%)
n
5
 = 10 
n (%)
n
6
 = 13 
n (%)
n
7
 = 10 
n (%)
n
8
 = 12 
n (%)
n
9
 = 6 
n (%)
027 34 (19.9) 27 (29.3) 4 (50.0) 3 (33.3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
014 27 (15.8) 15 (16.3) 1 (12.5) 1 (11.1) 3 (27.3) 1 (10.0) 3 (23.1) 1 (10.0) 1 (8.3) 1 (16.7)
053 18 (10.5) 15 (16.3) 2 (25.0) 1 (11.1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
078 9 (5.3) 4 (4.3) 0 (0) 0 (0) 1 (9.1) 1 (10.0) 1 (7.7) 0 (0) 1 (8.3) 1 (16.7)
002 8 (4.7) 2 (2.2) 0 (0) 0 (0) 2 (18.2) 0 (0) 0 (0) 3 (30.0) 1 (8.3) 0 (0)
Othera 75 (43.9) 29 (31.5) 1 (12.5) 4 (33.3) 5 (45.5) 8 (80.0) 9 (69.2) 6 (60.0) 9 (75.0) 4 (66.7)
a003, 005, 006, 010, 012, 017, 018, 019, 020, 029, 046, 049, 056, 070, 081, 126, 131, 220, 251, 403, 404, 419, 448, 538, 574, 642, 644, 645, 646, 650, 651, 
652, AI-12, AI-21, AI-3, AI-72, AI-75, AI-8, AI-82, AI-83, AI-9
Table 3 Results of the in vitro antimicrobial susceptibility testing of Clostridium difficile isolates according to European Com-
mittee on Antimicrobial Susceptibility Testing (EUCAST) minimal inhibitory concentration (MIC) and Clinical and Laboratory 
Standards Institute (CLSI) MIC breakpoints, respectively distributed by the five most frequent ribotypes among the study 
participants (N= 96)
Metronidazole n (%) Vancomycin n (%) Clindamycin n (%) Moxifloxacin n (%) Rifampicin n (%)
Ribo-
types
S 
(≤ 2 µg/
ml)
I R S 
(≤ 2 µg/
ml)
I R S 
(≤ 2 µg/
ml)
I  
(4 µg/
ml)
R  
(≥ 8 µg/
ml)
S  
(≤ 2 µg/
ml)
I  
(4 µg/
ml)
R  
(≥ 8 µg/
ml)
S  
(≤ 0.006 µg/
ml)
I R  
(≥ 32 g/
ml)
027 
(N1 = 34)
34 (100) 0 0 34 (100) 0 0 14 (41.2) 9 (26.5) 11 (32.4) 0 (0) 0 34 (100) 27 (79.4) 0 7 (20.6)
014 
(N2 = 27)
27 (100) 0 0 27 (100) 0 0 16 (59.3) 7 (25.9) 4 (14.8) 22 (81.5) 1 (3.7) 4 (14.8) 26 (96.3) 0 1 (3.7)
053 
(N3 = 18)
18 (100) 0 0 18 (100) 0 0 1 (5.6) 1 (5.6) 16 (88.9) 0 0 18 (100) 13 (72.2) 0 5 (27.8)
078 
(N4 = 9)
9 (100) 0 0 9 (100) 0 0 3 (33.3) 4 (44.4) 2 (22.2) 5 (55.6) 0 4 (44.4) 8 (88.9) 0 1 (11.1)
002 
(N5 = 8)
8 (100) 0 0 8 (100) 0 0 5 (62.5) 2 (25.0) 1 (12.5) 8 (100) 0 0 8 (100) 0 0
P-value 0.000 a 0.000 a 0.10 a
aFisher’s exact test
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accounted for 5 % of all isolates and was found in Vienna 
most (4 cases), and with one case each in ive other fed-
eral provinces in South, North, and West Austria, more 
rural areas. Only two of the nine RT 078 cases were clas-
siied as community acquired. Information on exposure 
to farm animals or on patients’ diet was not available. 
However, the over-representativeness of urban hospitals 
among the participating hospitals of our survey does not 
allow reliable conclusion on the origin of this particular 
ribotype in Austria.
A single ribotype—the RT 053—was identiied to be 
signiicantly associated with severe CDI, including need 
for intensive care, surgical treatment, or fatal outcome. 
While this association was still signiicant after adjust-
ment for age, no data on comorbidities were available to 
control for possible confounding of the observed asso-
ciation. he so-called hypervirulent ribotypes 027 and 
078 did not show an association with severe CDI or fatal 
outcome in our study. Our small study sample size might 
hinder any strong conclusions drawn from our ind-
ings, but previous publications have also reported lack 
of strong evidence for an association between the so-
called hypervirulent ribotypes or other strain character-
istics (such as mutation/deletions in tcdC or binary toxin 
production) and pathogen virulence [20, 26]. herefore, 
use of resource-consuming genotyping in guiding treat-
ment or infection control measures must be critically 
discussed. Barbut and Rupnik [27] stated that the most 
important control measure to be implemented is CDI 
surveillance and more timely response to a case, regard-
less of whether it is caused by a known or a newly emerg-
ing potential hyper-virulent genotype. Other experts 
recommend that ribotyping should be undertaken on 
all samples to detect not only outbreaks due to epidemic 
strains, but also outbreaks with non-epidemic strains, 
feasible due to poor environmental disinfection or other 
poor hygiene practices [28].
ince Vienna (accounting for 10 of the 18 participating 
hospitals). To account for the over-representativeness 
of Vienna hospitals, as well as for the diferent province 
population densities, we can consider a quarter of the 27 
cases of RT 027-infection in patients from Viennese hos-
pitals as representative. Together with the seven cases of 
RT 027 infection in patients from the two other eastern 
provinces (i.e., Burgenland, Lower Austria), these ind-
ings demonstrate a dominance of RT 027 in East-Austria, 
as compared to the other six Austrian provinces (no RT 
027 case observed).
C. diicile is an important nosocomial pathogen, as 
illustrated by our indings concerning 73 % of the 171 
CDI-cases acquired in the healthcare setting. he ive 
dominant ribotypes 027, 014, 053, 078, and 002 were 
similarly distributed among the health care-associated 
cases. No single ribotype was found to be associated with 
community acquisition. Our indings support the previ-
ous conclusion of Indra et al. [11], that C. diicile is still 
a pathogen of the health care facility setting. However, 
the total portion of community-acquired cases among 
the 171 CDI-cases was surprisingly high, at almost 20 %. 
In November 2008, among three Austrian hospitals par-
ticipating in a European study, only 8 % of the CDI cases 
documented were found to be community acquired [1]. 
Among CDI cases identiied in the USA within the Emerg-
ing Infections Program data in 2010, 52 % were already 
present at hospital admission, although they were largely 
health care facility related by means of outpatients and 
nursing home residents. he Centers for Disease Control 
and Prevention concluded that nearly all CDIs are related 
to various health care settings where predisposing antibi-
otics are prescribed and C. diicile transmission occurs 
[24].
PCR ribotype 078 has been detected frequently in 
farming animals, in retail meat products and was associ-
ated mainly with the community setting, indicating also 
a zoonotic transmission [8, 9, 25]. In our survey, RT 078 
Table 4 Epidemiological classification of the Clostridium difficile infection (CDI) cases and cases of severe CDI by the five 
most frequent ribotypes and others found among the study participants (N
total
=171)
Epidemiological classification Criteria for severe CDI
Ribotypes HA 
n (%) (95 %CI)
CA 
n (%)
Indeterminable 
n (%)
Surgical intervention 
n (%)
Intensive care
n (%)
30-day case fatality
n (%)
Total severe CDI
n (%)
027 (N
1
 = 34; 19.9 %) 29 (85.3) 
(70–94 %)
3 (8.8) 2 (5.9) 0 (0) 1 (2.9) 3 (8.8) 3 (8.8)
014 (N
2
 = 27; 15.8 %) 22 (81.5) 
(64–93 %)
4 (14.8) 1 (3.7) 1 (3.7) 2 (7.4) 3 (11.1) 4 (14.8)
053 (N
3
 = 18; 10.5 %) 13 (72.2) 
(49–89 %)
3 (16.7) 2 (11.1) 1 (5.6) 1 (5.6) 4 (22.2) 5 (27.8)
078 (N
4
 = 9; 5.3 %) 7 (77.8) 
(44–96 %)
2 (22.2) 0 (0) 0 (0) 1 (11.1) 0 (0) 1 (11.1)
002 (N
5
 = 8; 4.7 %) 5 (62.5) 
(28–89 %)
2 (25.0) 1 (12.5) 0 (0) 0 (0) 1 (12.5) 1 (12.5)
Other (N
6
 = 75) 49 (65.3) 
(54–75 %)
20 (26.7) 6 (8.0) 0 (0) 3(0) 4 (5.3) 5 (6.6)
TOTAL (N 
total
= 171) 125 (73.1) 34 (19.9) 12 (7.0) 2 (1.2) 8 (1.2) 15 (8.8) 19 (11.1)
original article
6  Clostridium diicile ribotypes in Austria: a multicenter, hospital-based survey 1 3
age number of CDI-cases per month. Moxiloxacin use 
was reduced from 1038 ± 109 deined daily doses (DDD) 
per month (January to May, period 1) to 42 ± 10 DDD per 
month (June to December, period 2) (P= 0.0045). Because 
use of any antimicrobial has the potential to induce the 
manifestation of CDI, antimicrobial stewardship pro-
grams that promote judicious use of antimicrobials, and 
environmental and infection control-related eforts must 
be encouraged [33, 34]. We hope that our study can con-
tribute to raise awareness and to support good medical 
practice in the ight against this often underestimated 
illness.
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